Calcineurin inhibitors for topical therapy in psoriasis

被引：6

作者：

Wohlrab J. ^{[1
,2
]}

机构：

[1] Universitätsklinik und Poliklinik für Dermatologie und Venerologie, Institut für Angewandte Dermatopharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle

[2] Universitätsklinik und Poliklinik für Dermatologie und Venerologie, Institut für Angewandte Dermatopharmazie, Martin-Luther-Universität Halle-Wittenberg, 06097 Halle

来源：

Der Hautarzt | 2006年 / 57卷 / 8期

关键词：

Calcineurin inhibitors; Pimecrolimus; Psoriasis; Tacrolimus; Topical therapy;

D O I：

10.1007/s00105-006-1185-9

中图分类号：

学科分类号：

摘要：

There are numerous possibilities for specific antiinflammatory therapy of psoriasis. One option is the use of calcineurin inhibitors. To date, only systemic administration of cyclosporine A is approved for this indication. Nonetheless cyclosporine A, tacrolimus and pimecrolimus can all be classed as effective anti-inflammatory agents for the therapy of psoriasis. Unfortunately, the vehicles currently available do not insure adequate topical delivery of these substances. Clinical efficacy of the preparations can be proven only when additional penetration-promoting measures are used or penetration-facilitating conditions exist. The entire group can be expected to play a greater role in the topical therapy of psoriasis if advances in vehicles and delivery systems are made. © Springer Medizin Verlag 2006.

引用

页码：685 / 689

页数：4

共 37 条

[1]

Amichai B., Psoriasis of the glans penis in a child successfully treated with Elidel (pimecrolimus) cream, J Eur Acad Dermatol Venereol, 18, pp. 742-743, (2004)

[2]

Bigby M., Pimecrolimus and tacrolimus for the treatment of intertriginous and facial psoriasis: Are they effective?, Arch Dermatol, 141, pp. 1152-1153, (2005)

[3]

Billich A., Vyplel H., Grassberger M., Et al., Novel cyclosporin derivates featuring enhanced skin penetration despite increased molecular weight, Bioorg Med Chem, 13, pp. 3157-3167, (2005)

[4]

Bousema M.T., Tank B., Heule F., Et al., Placebo-controlled study of psoriasis patients treated topically with a 10% cyclosporine gel, J Am Acad Dermatol, 22, pp. 126-127, (1990)

[5]

Bu-Elmagd K., Van T.D., Jegasothy B.V., Ackerman C.D., Et al., FK 506: A new therapeutic agent for severe recalcitrant psoriasis, Transplant Proc, 23, pp. 3322-3324, (1991)

[6]

Choi H.K., Flynn G.L., Amidon G.L., Percutaneous absorption and dermal delivery of cyclosporin A, J Pharm Sci, 84, pp. 581-583, (1995)

[7]

Erdogan M., Wright Jr. J.R., McAlister V.C., Liposomal tacrolimus lotion as a novel topical agent for treatment of immune-mediated skin disorders: Experimental studies in a murine model, Br J Dermatol, 146, pp. 964-967, (2002)

[8]

Freeman A.K., Linowski G.J., Brady C., Et al., Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas, J Am Acad Dermatol, 48, pp. 564-568, (2003)

[9]

Gottlieb A.B., Griffiths C.E., Ho V.C., Et al., Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: A double-blind, multicentre, randomized, dose-finding trial, Br J Dermatol, 152, pp. 1219-1227, (2005)

[10]

Grassberger M., Steinhoff M., Schneider D., Luger T.A., Pimecrolimus - An anti-inflammatory drug targeting the skin, Exp Dermatol, 13, pp. 721-730, (2004)

← 1 2 3 4 →